3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Hodgkin Disease
1
Fallopian Tube Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Carboplatin
23
Paclitaxel
14
pembrolizumab
8
liposomal doxorubicin
7
Bevacizumab
5
Specimen Handling
4
Cyclophosphamide
4
olaparib
3
niraparib
3
epacadostat
3
Topotecan
3
Taxes
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Biopsy
3
sarilumab
2
rucaparib
2
poly ICLC
2
durvalumab
2
cemiplimab
2
STA 9090
2
Injections
2
Immunoglobulin G
2
Drug Therapy
2
Docetaxel
2
Disulfides
2
Cisplatin
2
veliparib
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Fallopian Tube Neoplasms
×
Blood Component Removal
×
Clear all
NCT05920798
2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2
Recruiting
40 enrolled